Open AccessSurvival Outcomes After Adding Stereotactic Body Radiotherapy to Metastatic Renal Cell Carcinoma Patients Treated With Tyrosine Kinase Inhibitors
Author(s) -
Liru He,
Yang Liu,
Hui Han,
Zhuowei Liu,
ShuChun Huang,
Wufei Cao,
Bo-Ji Liu,
Zike Qin,
Shengjie Guo,
Zhiling Zhang,
Mang Lin,
Xiaobo Jiang,
Chuyong Lin,
Yonghong Li,
Kai Yao,
Pei Dong,
Fangjian Zhou
Publication year - 2019
Publication title -
american journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.896
H-Index - 78
eISSN - 1537-453X
pISSN - 0277-3732
DOI - 10.1097/coc.0000000000000622
Subject(s) - medicine , renal cell carcinoma , urology , radiation therapy , toxicity , tyrosine kinase inhibitor , oncology , carcinoma , gastroenterology , surgery , cancer
Long-lasting control is rarely achieved with tyrosine kinase inhibitors (TKI) alone in metastatic renal cell carcinoma (mRCC). Our study aimed to investigate the survival outcomes of adding stereotactic body radiotherapy (SBRT) to TKI in mRCC.